Our Mission
Our Mission is to improve the lives of patients suffering from difficult to treat cancers by developing a broad spectrum immunomodulator that primes and boosts the immune response and enhance the performance of cancer treatment.
About Us
Immodulon is a late-stage clinical biotechnology company developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. Immodulon is developing IMM-101, a heat-killed Mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumours including those considered to be immunologically “cold,” such as pancreatic cancer.
Latest from Immodulon
Precision-Panc Team Open the PRIMUS-006 Study, a Novel Combination of IMM-101, Gemcitabine and Pembrolizumab
– PRIMUS-006 study led by Professors David Chang and Jeff Evans of the University of Glasgow – – Phase II study is evaluating a novel combination in first-line metastatic pancreatic cancer – GLASGOW, United Kingdom, June 18, 2024 (GLOBE NEWSWIRE) -- The Precision-Panc...
Immodulon to Participate in the Wells Fargo Virtual Private Biotech Symposium
Uxbridge, United Kingdom – April 29, 2024 – Immodulon, a late-stage clinical biotechnology company focused on developing a broad spectrum immunomodulator to improve the lives of patients suffering from difficult-to-treat cancers, today announced that Gertjan Bartlema,...
Immodulon Announces Formation of New Scientific Advisory Board to Support Late-stage Clinical Development of IMM-101
Professor Dr. med. Thomas Seufferlein appointed Chair of new Scientific Advisory Board (SAB) composed of leaders with deep expertise in the clinical oncology field New SAB to complement significant oncology drug development experience of Immodulon’s new management...